ACP Issues Clinical Guideline for Pharmacologic Treatment of Acute Episodic Migraine

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on March 21, 2025.

By Elana Gotkine HealthDay Reporter

FRIDAY, March 21, 2025 -- In a clinical guideline issued by the American College of Physicians (ACP) and published online March 18 in the Annals of Internal Medicine, recommendations are presented for the pharmacologic treatment of acute episodic migraine headache in the outpatient setting.

Amir Qaseem, M.D., Ph.D., from the ACP in Philadelphia, and colleagues examined the comparative benefits and harms of pharmacologic treatments of acute episodic migraine headache, patients' values and preferences, and economic evidence relating to the treatments. The guidelines were designed for physicians and other clinicians and related to adults with acute episodic migraine headache (defined as one to 14 headache days per month) managed in outpatient settings.

The authors presented two recommendations. For nonpregnant adults who do not respond adequately to a nonsteroidal anti-inflammatory drug, ACP recommends the addition of a triptan to treat moderate-to-severe acute episodic migraine headache in outpatient settings (strong recommendation; moderate-certainty evidence). For nonpregnant adults who do not respond adequately to acetaminophen, ACP suggests that clinicians add a triptan to treat moderate-to-severe acute episodic migraine headache in outpatient settings (conditional recommendation; low-certainty evidence).

"There is a critical need for funding agencies, such as the Patient-Centered Outcomes Research Institute or National Institute of Neurological Disorders and Stroke, to support well-designed, comparative effectiveness trials of newer medications to treat moderate-to-severe episodic migraine compared with the combination of a triptan and an NSAID or acetaminophen," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-03-22 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords